From a research standpoint, urinary CCL14 may represent an innovative mechanistic surrogate endpoint used to evaluate novel therapeutic targets for the prevention of persistent severe AKI and its sequelae [5]. The gene discussed is CCL14; the disease is acute kidney injury.